Last checked at 22 Apr 2020 15:13
22 April 2020
Futura Medical plc
Director Shareholding
Futura Medical Plc (AIM: FUM) ("Futura" or "the Company") today received notification that on 22 April 2020, James Barder, the Company's CEO, sold 173,000 ordinary shares of 0.2 pence in the Company ("Ordinary Shares") at a price of 11.50 pence per share and repurchased 173,000 Ordinary Shares at a price of 11.52 pence per share. These trades were carried out as part of a "Bed and ISA" process, allowing James to move his existing shareholding into an ISA.
Following these trades James Barder's beneficial holding remains unchanged at 1,093,472 ordinary shares with an aggregate beneficial and non-beneficial holding of 1,210,972 Ordinary Shares, representing 0.49 per cent. of the current total voting rights of the Company. James Barder also has options over 1,750,000 Ordinary Shares.
Further details are contained within the notification below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.
For further information please contact:
Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:LiberumBidhi Bhoma/ Euan Brown/ Kane CollingsTel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| James Barder
| |||
2
| Reason for the notification
| ||||
a)
| Position/status
| CEO | |||
b)
| Initial notification /Amendment
| Initial | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Futura Medical Plc | |||
b)
| LEI
| 21380053QLT46UNV2303 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 0.2 pence | |||
Identification code | ISIN: GB0033278473 | ||||
b)
| Nature of the transaction
| Transfer of 173,000 Ordinary Shares, via sale and repurchase | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
11.50p | 173,000 (sale) | ||||
11.52p | 173,000 (purchase) | ||||
d)
| Aggregated information | ||||
- Aggregated volume - Price - Total
- Aggregated volume - Price - Total
| 173,000 (sale) 11.50p £19,895.00
173,000 (purchase) 11.52p £19,929.60 | ||||
e)
| Date of the transaction
| 22 April 2020 | |||
f)
| Place of the transaction
| London Stock Exchange, AIM Market (XLON) | |||